Welcome to our dedicated page for Solid Bioscience SEC filings (Ticker: SLDB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Solid Biosciences Inc. (SLDB) files reports and disclosures with the U.S. Securities and Exchange Commission as a Nasdaq-listed issuer. These SEC filings provide detailed information on the company’s clinical programs, financial condition, risk factors and material corporate events related to its development of precision genetic medicines for rare neuromuscular and cardiac diseases.
Among the documents available, Form 10-K annual reports and Form 10-Q quarterly reports typically discuss Solid Biosciences’ gene therapy pipeline, including SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich’s ataxia, SGT-501 for catecholaminergic polymorphic ventricular tachycardia and SGT-601 for TNNT2-mediated dilated cardiomyopathy, along with its AAV-SLB101 capsid platform and broader development activities. These filings outline the company’s business description, research and development focus and key risks.
Form 8-K current reports, such as the filing describing interim data from the INSPIRE DUCHENNE Phase 1/2 trial of SGT-003, provide updates on material events, including clinical data readouts, regulatory developments, corporate presentations and other significant announcements. Investors can also review information on equity awards and stock plans, as referenced in company communications about inducement grants made under Nasdaq Listing Rule 5635(c)(4).
This SEC filings page offers real-time access to Solid Biosciences’ submissions from the EDGAR system, along with AI-powered summaries that highlight key points from lengthy documents. Users can quickly identify disclosures on clinical trial progress, gene therapy strategy, regulatory interactions and other factors that may be important when evaluating SLDB.
SLDB insider Jessie Harahan filed a Form 144 indicating an intent to sell up to 26,535 shares of common stock through E*TRADE Financial on the NASDAQ, with an approximate aggregate market value of $170,803.14.
The shares were acquired on 02/02/2026 via settlement of performance shares from the issuer as compensation. The filing notes 82,561,235 shares of common stock outstanding and discloses a prior sale over the past three months of 4,483 shares for gross proceeds of $22,908.13.
A holder of SLDB common stock has filed a notice of proposed sales under Rule 144. The filing covers 28,335 shares of common stock, to be sold through E*TRADE Financial Corporation on 02/02/2026 on the NASDAQ, with an aggregate market value of $182,389.56. These shares were acquired on the same date through settlement of performance share awards as compensation from the issuer. The filing reports that 82,561,235 shares of this class were outstanding, and indicates no other sales by this holder in the past three months.
Kevin Tan has filed a notice to sell SLDB common stock under Rule 144. The planned sale covers 26,837 shares of common stock through E*TRADE Financial, with an aggregate market value of $172,747.09, to be sold on or about February 2, 2026 on NASDAQ.
These shares were acquired on February 2, 2026 via settlement of performance shares as compensation from the issuer. In the previous three months, Kevin Tan also sold 5,704 shares of common stock on January 13, 2026, generating gross proceeds of $30,060.08. Shares outstanding were 82,561,235 at the time listed.
Solid Biosciences insider Form 144 filing shows a planned sale of 80,258 shares of common stock through E*TRADE Financial on or after 02/02/2026, with an aggregate market value of $516,612.72. The filing notes 82,561,235 shares outstanding and a prior sale of 10,808 shares for $55,228.88 in the past three months.
Solid Biosciences insider David T. Howton has filed a notice of proposed stock sales under Rule 144. The filing covers 37,771 shares of common stock with an aggregate market value of $243,128.15, to be sold through E*TRADE Financial Corporation on NASDAQ around 02/02/2026.
The shares were acquired on 02/02/2026 via settlement of performance shares as compensation from the issuer. Over the prior three months, the same insider sold 4,932 common shares on 12/03/2025 for gross proceeds of $25,202.52.
A holder of SLDB common stock, Paul Herzich, has filed a notice of intent to sell up to 26,250 shares through E*TRADE on the NASDAQ, with an aggregate market value of $168,968.63. The issuer had 82,561,235 shares outstanding and the approximate sale date is February 2, 2026.
The shares to be sold were acquired on February 2, 2026 via settlement of performance shares from the issuer as compensation. Over the prior three months, Herzich sold 2,701 shares of common stock on December 3, 2025, generating gross proceeds of $13,802.11.
Solid Biosciences Inc. director Ilan Ganot reported routine equity compensation activity and a small tax-related share sale. On January 27, 2026, previously granted restricted stock units converted one-for-one into common stock, including 389 shares for his wife and 3,884 shares for him.
On January 28, 2026, 191 common shares indirectly held through his wife were sold at $6.59 per share to cover withholding taxes under a pre-established automatic sell-to-cover instruction and were not a discretionary trade. Following these events, he beneficially owns 95,255 shares individually, 4,042 shares jointly with Annie Ganot, 17,476 shares indirectly through his wife, and 19,394 shares through the Ilan Ganot 2017 Irrevocable Trust.
Solid Biosciences Inc. CFO & Treasurer Kevin Tan reported routine equity transactions. On January 9, 2026, 11,250 restricted stock units (RSUs) converted into the same number of common shares at an exercise price of $0.00, reflecting scheduled vesting. On January 13, 2026, he sold 5,704 shares of common stock at $5.27 per share.
According to the disclosure, this sale was made solely to cover withholding taxes under an automatic “sell-to-cover” instruction adopted on August 15, 2024, and is described as not a discretionary trade by Mr. Tan. After these transactions, he directly holds 46,100 shares of common stock and 11,250 RSUs, with RSUs converting to common stock on a one-for-one basis and vesting in four equal annual installments from January 9, 2023.
A holder of SLDB common stock filed a notice of proposed sale on Form 144 covering 5,704 shares. These shares were acquired on 01/09/2026 through the settlement of vested restricted stock units from the issuer as compensation. The planned sale is indicated through E*TRADE Financial Corporation, with an approximate aggregate market value of 30,060.08 and an expected sale date of 01/13/2026 on the NASDAQ. The issuer reports 79,162,201 common shares outstanding, providing context for the relative size of this planned transaction.
Solid Biosciences director Ian F. Smith reported multiple equity award transactions. On 01/02/2026, he received a stock option for 18,012 shares of common stock at an exercise price of $5.45 per share and a grant of 13,761 restricted stock units (RSUs). These “Smith Equity Awards” vest in equal quarterly installments over 12 months from the grant date, with full acceleration if the Smith Agreement ends early or there is a change in control of the company.
On 01/06/2026, 4,573 previously granted RSUs fully vested and converted to 4,573 shares of common stock on a one‑for‑one basis. After these transactions, Smith directly held 131,264 shares of Solid Biosciences common stock, along with 18,012 options and 13,761 RSUs.